NMT, AGA Medical Pursue PFO Indication Following Septal Defect Approvals
This article was originally published in The Gray Sheet
Executive Summary
Nitinol Medical Technologies' CardioSeal approval for ventricular septal defects Dec. 5 paves the way for pursuit of expanded approval to treat the much larger population with patent foramen ovale, the firm says
You may also be interested in...
NMT Looking To Broaden STARFlex Indication In Wake Of Panel Outcome
NMT Medical is in discussions with FDA on the design of a trial to support a general stroke-prevention indication for its STARFlex patent foramen ovale (PFO) occluder
NMT Looking To Broaden STARFlex Indication In Wake Of Panel Outcome
NMT Medical is in discussions with FDA on the design of a trial to support a general stroke-prevention indication for its STARFlex patent foramen ovale (PFO) occluder
NMT STARFlex Single-Arm Study Insufficient For Approval, Panel Concludes
NMT Medical must conduct a randomized controlled trial of the STARFlex septal occlusion system to demonstrate that the device is superior to medical therapy in preventing strokes, FDA's Circulatory System Devices Panel concluded at its Sept. 10 meeting in Gaithersburg, Maryland